Pembrolizumab plus pemetrexed and carboplatin can improve overall survival for advanced nonsquamous non–small cell lung cancer
Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is a more life-threatening type among lung cancer, accounting for about 80% to 85% of lung cancers. A pemetrexed...